Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.21.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating expenses:    
Research and development $ 8,021 $ 5,104
General and administrative 2,765 2,960
Total operating expenses 10,786 8,064
Loss from operations (10,786) (8,064)
Other income:    
Interest income 24 70
Change in fair value of warrant liabilities 5,567 416
Total other income 5,591 486
Net loss $ (5,195) $ (7,578)
Per share information:    
Net loss per share of common stock, basic and diluted $ (0.18) $ (0.49)
Basic and diluted weighted average shares outstanding 28,963,594 15,332,042